Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 1, 2015, Pages 102-110

  Willecke, Florian ^a,b   Scerbo, Diego ^a,b   Nagareddy, Prabhakara ^c   Obunike, Joseph C ^d   Barrett, Tessa J ^a   Abdillahi, Mariane L ^a,b   Trent, Chad M ^a,b   Huggins, Lesley A ^a,b   Fisher, Edward A ^a   Drosatos, Konstantinos ^e   Goldberg, Ira J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; hypertriglyceridemia; lipoprotein lipase

Indexed keywords

INSULIN; INSULIN RECEPTOR; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENE EXPRESSION; HEART; HEPATIC LIPOGENESIS; HYPERTRIGLYCERIDEMIA; INSULIN DEFICIENCY; KNOCKOUT MOUSE; LIPOGENESIS; LIPOLYSIS; MOUSE; NONHUMAN; SKELETAL MUSCLE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; CHEMICALLY INDUCED; DEFICIENCY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; POSTPRANDIAL STATE; SIGNAL TRANSDUCTION; TIME FACTOR;

ADIPOSE TISSUE, BROWN; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; HYPERTRIGLYCERIDEMIA; INSULIN; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN LIPASE; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; MYOCARDIUM; POSTPRANDIAL PERIOD; PPAR ALPHA; PPAR DELTA; RNA, MESSENGER; SIGNAL TRANSDUCTION; STREPTOZOCIN; TIME FACTORS; TRIGLYCERIDES;

EID: 84920268071     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304615     Document Type: Article

References (63)

1. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientifc statement from the American Heart Association. Circulation. 2011;123:2292-2333.
2. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol. 2011;31:1716-1725.
3. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150-159.
4. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531-537.
5. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7:95-96.
6. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87-97.
7. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is suf-fcient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008;7:125-134.
8. Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 2009;10:405-418.
9. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280:140-146.
10. Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012;1821:819-825.
11. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E829-E835.
12. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 2004;114:659-668.
13. Matsuzaka T, Shimano H, Yahagi N, et al. Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes. 2004;53:560-569
14. Foufelle F, Ferré P. New perspectives in the regulation of hepatic gly-colytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002;366[pt 2]:377-391.
15. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002;43:1997-2006.
16. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297:E271-E288.
17. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specifc transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-5348.
18. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The per-oxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003;17:2477-2493.
19. Li L, Beauchamp MC, Renier G. Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis. 2002;165:101-110.
20. Kako Y, Massé M, Huang LS, Tall AR, Goldberg IJ. Lipoprotein lipase defciency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res. 2002;43:872-877.
21. Levak-Frank S, Radner H, Walsh A, Stollberger R, Knipping G, Hoefer G, Sattler W, Weinstock PH, Breslow JL, Zechner R. Muscle-specifc overex-pression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest. 1995;96:976-986.
22. Bishop JR, Foley E, Lawrence R, Esko JD. Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate. J Biol Chem. 2010;285:14658-14662.
23. Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P. Liver carbohydrate and lipid metabolism of insulin-defcient mice is altered by trans-10, cis-12 conjugated linoleic acid. J Nutr. 2009;139:1901-1907.
24. Reaven EP, Reaven GM. Mechanisms for development of diabetic hyper-triglyceridemia in streptozotocin-treated rats. Effect of diet and duration of insulin defciency. J Clin Invest. 1974;54:1167-1178.
25. O'Looney P, Irwin D, Briscoe P, Vahouny GV. Lipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes. J Biol Chem. 1985;260:428-432.
26. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997;40:454-462.
27. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-1236.
28. Taskinen MR, Adiels M, Westerbacka J, Söderlund S, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Olofsson SO, Orho-Melander M, Borén J. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144-2150.
29. Shojaee-Moradie F, Ma Y, Lou S, Hovorka R, Umpleby AM. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes. 2013;62:4063-4069.
30. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofsson SO, Yki-Järvinen H, Borén J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765.
31. Siler SQ, Neese RA, Parks EJ, Hellerstein MK. VLDL-triglyceride production after alcohol ingestion, studied using [2-13C1] glycerol. J Lipid Res. 1998;39:2319-2328.
32. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL, Getz GS, Polonsky KS. Fasting hypertriglyceridemia in noninsulin-depen-dent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab. 1991;72:934-944.
33. De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest. 1996;26:89-108.
34. Brunzell JD, Porte D Jr, Bierman EL. Reversible abnormalities in pos-theparin lipolytic activity during the late phase of release in diabetes mellitus (postheparin lipolytic activity in diabetes). Metabolism. 1975;24:1123-1137.
35. Morino K, Petersen KF, Sono S, Choi CS, Samuel VT, Lin A, Gallo A, Zhao H, Kashiwagi A, Goldberg IJ, Wang H, Eckel RH, Maegawa H, Shulman GI. Regulation of mitochondrial biogenesis by lipoprotein lipase in muscle of insulin-resistant offspring of parents with type 2 diabetes. Diabetes. 2012;61:877-887.
36. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb. 1991;11:1192-1203.
37. Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574
38. Brosius F. Low-dose streptozotocin induction protocol (mouse). Animal Models of Diabetic Complications Consortium. 2003 www.diacomp.org/shared/showFile.aspx?doctypeid=3&docid=19. Accessed Sepember 9, 2014.
39. Towle HC. Glucose as a regulator of eukaryotic gene transcription. Trends Endocrinol Metab. 2005;16:489-494.
40. Poupeau A, Postic C. Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors. Biochim Biophys Acta. 2011;1812:995-1006.
41. Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab. 2010;12[suppl 2]:83-92.
42. Jindrichova E, Kratochvilova S, Kovar J. Glucose administration down-regulates lipoprotein lipase activity in vivo: a study using repeated intravenous fat tolerance test. Physiol Res. 2007;56:175-181
43. Kovar J, Fejfarova V, Pelikanova T, Poledne R. Hyperglycemia down-regulates total lipoprotein lipase activity in humans. Physiol Res. 2004;53:61-68
44. Kern PA, Mandic A, Eckel RH. Regulation of lipoprotein lipase by glucose in primary cultures of isolated human adipocytes. Relevance to hypertriglyceridemia of diabetes. Diabetes. 1987;36:1238-1245.
45. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Dapaglifozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
46. Chen YD, Coulston AM, Zhou MY, Hollenbeck CB, Reaven GM. Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? Diabetes Care. 1995;18:10-16.
47. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an athero-genic disorder common in patients with diabetes mellitus. Am J Cardiol. 2001;88(6A):9H-15H.
48. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A. Ciprofbrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000;101:1773-1779.
49. Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci. 2001;6:D388-D405.
50. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta. 2014;1841:919-933.
51. Garcia-Arcos I, Hiyama Y, Drosatos K, Bharadwaj KG, Hu Y, Son NH, O'Byrne SM, Chang CL, Deckelbaum RJ, Takahashi M, Westerterp M, Obunike JC, Jiang H, Yagyu H, Blaner WS, Goldberg IJ. Adipose-specifc lipoprotein lipase defciency more profoundly affects brown than white fat biology. J Biol Chem. 2013;288:14046-14058
52. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg IJ, Shachter NS. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest. 2000;105:1807-1818.
53. Aktin E, Meng HC. Release of clearing factor lipase (lipoprotein lipase) in vivo and from isolated perfused hearts of alloxan diabetic rats. Diabetes. 1972;21:149-156.
54. Rauramaa R, Kuusela P, Hietanen E. Adipose, muscle and lung tissue lipo-protein lipase activities in young streptozotocin treated rats. Horm Metab Res. 1980;12:591-595.
55. Staiger H, Haas C, Machann J, Werner R, Weisser M, Schick F, Machicao F, Stefan N, Fritsche A, Häring HU. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes. 2009;58:579-589.
56. Heller F, Harvengt C. Effects of clofbrate, bezafbrate, fenofbrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol. 1983;25:57-63.
57. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung. 1990;40(2 pt 1):156-162.
58. Weisweiler P. Low-dose colestipol plus fenofbrate: effects on plasma lipoproteins, lecithin: cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia. Metabolism. 1989;38:271-274.
59. Shalev A, Siegrist-Kaiser CA, Yen PM, Wahli W, Burger AG, Chin WW, Meier CA. The peroxisome proliferator-activated receptor alpha is a phos-phoprotein: regulation by insulin. Endocrinology. 1996;137:4499-4502.
60. Wilson DE, Hata A, Kwong LK, Lingam A, Shuhua J, Ridinger DN, Yeager C, Kaltenborn KC, Iverius PH, Lalouel JM. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyc-eridemia, pancreatitis, and non-insulin-dependent diabetes. J Clin Invest. 1993;92:203-211.
61. Shimada M, Ishibashi S, Gotoda T, Kawamura M, Yamamoto K, Inaba T, Harada K, Ohsuga J, Perrey S, Yazaki Y. Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hyper-triglyceridemia and hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:1688-1694.
62. Nikkilä EA, Huttunen JK, Ehnholm C. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma tri-glyceride metabolism. Diabetes. 1977;26:11-21.
63. Marçais C, Bernard S, Merlin M, Ulhmann M, Mestre B, Rochet-Mingret L, Revol A, Berthezene F, Moulin P. Severe hypertriglyceridaemia in type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 defciency. Diabetologia. 2000;43:1346-1352.